Aprea Therapeutics, Inc. (APRE): Total Assets
$15.93M
As of 2025-12-31
$42.29M
As of 2026-06-30
-19.2%
3-year compound annual growth
-29.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.93M | -33.6% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $23.98M | +5.9% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $22.65M | -24.9% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $30.16M | -46.9% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $56.82M | -38.8% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $92.81M | -30.5% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $133.61M | +102.4% | 2021-03-16, Balance as of period end |
| 2018-12-31 | $66.02M | n/a | 2020-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $15.93M | -33.6% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $15.92M | +2.7% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $16.08M | -25.5% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $15.45M | -22.1% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $16.52M | -48.6% |
| Cingulate Inc. (CING) | 2025-12-31 | $15.07M | +1.4% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $16.93M | -59.2% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $14.98M | -41.2% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $17.01M | -24.5% |
Compare APRE, RVPH, ANIX, SYBX side by side · Screen every company in Pharmaceutical Preparations ↗